SCHEMBL3045360

SCHEMBL3045360

CN([C@@H](CN1CCOCC1)c1ccc(Br)cc1)[C@@H](CN1CCOCC1)c1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
ALOX12 P18054 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TSHR P16473 3/20 0.47
USP2 O75604 1/20 0.47
HSP90AA1 P07900 1/20 0.46
NTSR1 P30989 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
MPI P34949 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP3A4 P08684 4/20 0.40
CYP2D6 P10635 4/20 0.40
OPRK1 P41145 4/20 0.40
UTS2R Q9UKP6 4/20 0.40
IGF1R P08069 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3228765 0.80 ALDH1A1 (0.53) ALDH1A1KDM4EALOX12NPSR1L3MBTL1
SCHEMBL14438299 0.78 MEN1 (0.49) ALDH1A1KDM4ETSHRKMT2AMEN1
SCHEMBL2947236 0.76 TSHR (0.50) ALDH1A1KDM4EALOX12NPSR1L3MBTL1
SCHEMBL14452546 0.76 POLB (0.51) ALDH1A1KDM4EL3MBTL1TSHRKMT2A
SCHEMBL27775273 0.76 TSHR (0.50) ALDH1A1KDM4EALOX12NPSR1L3MBTL1
SCHEMBL4071246 0.76 KDM4E (0.71) ALDH1A1KDM4EALOX12NPSR1L3MBTL1
SCHEMBL2947238 0.76 TSHR (0.50) ALDH1A1KDM4EALOX12NPSR1L3MBTL1
SCHEMBL2950084 0.76 KDM4E (0.71) ALDH1A1KDM4EALOX12NPSR1L3MBTL1
SCHEMBL27775260 0.76 TSHR (0.50) ALDH1A1KDM4EALOX12NPSR1L3MBTL1
SCHEMBL2954493 0.76 ALDH1A1 (0.47) ALDH1A1KDM4EALOX12NPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256130-A1 MORPHOLINYL AND PYRROLIDINYL ANALOGS GOODMAN KRISTA B 2010-10-07 US disclosed
US-7749998-B2 Morpholinyl and pyrrolidinyl analogs GLAXOSMITHKLINE LLC (US) 2010-07-06 US disclosed
US-20090275571-A1 MORPHOLINYL AND PYRROLIDINYL ANALOGS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US disclosed
US-7432258-B2 Morpholinyl and pyrrolidinyl analogs SMITHKLINE BEECHAM CORPORATION (US) 2008-10-07 US disclosed
US-20080021023-A1 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension GLAXOSMITHKLINE LLC 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256130-A1 MORPHOLINYL AND PYRROLIDINYL ANALOGS UTS2R, AVPR2, VIPR2 ALDH1A1 4201/4885KDM4E 4642/4885ALOX12 3417/4885
US-20090275571-A1 MORPHOLINYL AND PYRROLIDINYL ANALOGS UTS2R, AVPR2, VIPR2 ALDH1A1 4201/4885KDM4E 4642/4885ALOX12 3417/4885
US-20080021023-A1 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension UTS2R, PLAUR, FABP3 ALDH1A1 290/4885KDM4E 2515/4885ALOX12 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.